The progress of maintenance therapy in advanced non-small cell lung cancer

Abstract

Abstract: The morbidity and mortality of lung cancer showed a trend of increased year by year, the vast majority of lung cancer is non-small cell lung cancer (NSCLC),and more than half diagnosed patients are stage ⅢB or Ⅳ, chemotherapy is the main treatment approaches for patients with this kind of, but 5 years of survival rate is only 5% to 11%.Maintennance treatment is one of the hot research topic in the field how to improve time recurrence and survival time in recent years.This paper reviewed recent advances in the maintenance treatment for NSCLC.

Key words: Carcinoma, Non-small cell lung, Maintenance therapy

CLC Number:

R734.2

YE Chong-yang, XIE Jia-zheng. The progress of maintenance therapy in advanced non-small cell lung cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(10): 1192-1195.

References

[1] Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database[J]. J Clin Oncol, 2006, 24(28): 4539-4544.
[2] 程婷婷, 杨谨. 晚期非小细胞肺癌维持治疗的研究进展[J]. 中华肿瘤防治杂志, 2011, 18(20): 1651-1655.
[3] 顾亮, 赵恬, 钦光跃. 吉非替尼对比培美曲塞二线治疗晚期非小细胞肺癌的临床研究[J]. 中国临床药理学与治疗学, 2012, 17(5): 569-573.
[4] Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase Ⅲ trial[J]. Lung Cancer, 2006, 52(2): 155-163.
[5] Belani CP, Waterhouse DM, Ghazal H, et al. Phase Ⅲ study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine- carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC) [J]. J Clin Oncol, 2010, 28(Suppl 7506): S540.
[6] Calvert H. An overview of folate metabolism: features relevgnt to the action and toxicities of antifolate anticancer agents[J]. Semin Oncol, 1999, 26(2 Supp16): 3-10.
[7] Ciuleanu T, Brodowicz T, Zielinski C, et al. Mainteance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, doubleblind, phase Ⅲ study [J]. Proc Am Soc Clin Oncol, 2009, 374(9699): 1432-1440.
[8] Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after frontline therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer[J]. J Clin Oncol, 2009, 27(4): 591-598.
[9] 赵峥, 杨晓光, 苏春勇, 等. 应用紫杉醇脂质体治疗非小细胞肺癌术后淋巴结转移的临床观察[J].中国医师进修杂志, 2013, 36(2): 31-33.
[10] Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage ⅢB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation[J]. J Clin Oncol, 2003, 21(15): 2933-2939.
[11] Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial INTACT1[J]. J Clin Oncol, 2004, 22(5): 777-784.
[12] Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial INTACT 2[J]. J Clin Oncol, 2004, 22(5): 785-794.
[13] Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the tarceva lung cancer investigation trial[ J]. J Clin Oncol, 2007, 25(12): 1545- 1552.
[14] Herbst RS, Prager D, Hermann R, et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer[J]. J Clin Oncol, 2005, 23( 25): 5892- 5899.
[15] Solit DB, She Y, Lobo J, et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel[J]. Clin Cancer Res, 2005, 11(5): 1983-1989.
[16] Davies AM, Ho C, Lara PN, et al. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinaseinhibitors and chemotherapy in non-small cell lung cancer[J]. Clin Lung Cancer, 2006, 7(6): 385-388.
[17] Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN:a double-blind,randomized,phase III study of maintenance edotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC[S]. Florida: ASCO Annual Meeting, 2009: 8001.
[18] Hida T, Okamoto I, Kashii T, et al. Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in Japanese patients with advanced non-small cell lung cancer(NSCLC): results of a west Japan Thoracic Oncology Group trial(WJTOG0)[S]. Chicago: ASCO Annual Meeting, 2008: LBA8012.